About
Dr. Georges has 15 years expertise in the field of molecular & cellular immunology and T cell vaccine development. He was co-founder and Chief Technology Officer of Immune Targeting Systems (ITS) Limited from 2004 until its acquisition by us in March 2015. Prior to ITS, Dr. Georges held the position of head of immunology at SEDAC-Therapeutics from 1999 until 2003. Dr. Georges has significant experience in product formulation and manufacturing, preclinical and early clinical development with a focus on peptide-based vaccines. Dr. Georges has a special interest in designing vaccines against infectious diseases and cancer and has developed T cell epitope identification methodologies combining in silico, in vitro and in vivo approaches. He received his Ph.D. in Molecular Immunology from the Pasteur Institute and is the co-author of 18 publications and co-inventor of 11 patent families.
Position in the VCSift Database
- • 2 investors at Altimmune are tracked.
- • 181 investors hold the Chief Technology Officer role in VCSift. Bertrand Georges is one of them.
- • 28 investors are based in Gaithersburg, Maryland, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Gaithersburg, US
Contact Information
Find more investors like Bertrand
Search Investors